Skip to main content

Diagnostik: Fibrosescores

  • Chapter
  • First Online:
Nicht-alkoholische Fettlebererkrankung
  • 982 Accesses

Zusammenfassung

Nach der Diagnosestellung einer nicht-alkoholischen Fettlebererkrankung (NAFLD) ist eine frühzeitige Prognoseabschätzung von wesentlicher Bedeutung und bestimmt den weiteren diagnostischen Ablauf. Diese erste Beurteilung des Patienten findet idealerweise bereits in der Primärversorgungssituation statt. Hierfür stehen eine Reihe von laborbasierten Fibrosescores zur Verfügung, die frei verfügbar und kostengünstig sind (FIB-4, NFS, APRI). Die Primärbeurteilung sollte unbedingt mittels kombinierter laborbasierter Fibrosescores erfolgen. Es gilt, Patienten mit fehlender oder geringer Fibrose und entsprechend guter Prognose von denen mit fortgeschrittener Fibrose zu unterscheiden, die beim Spezialisten vorgestellt werden sollten. Falsch-positive Testergebnisse von FIB-4 und NFS in der Altersgruppe > 65 Jahre können durch altersspezifische Cut-offs korrigiert werden. Die direkten, kostenintensiven Fibrosetests sind den indirekten günstigeren Scores nicht wesentlich überlegen. Die weiterführende Diagnostik mittels Elastometrie dient der Einschränkung des diagnostischen Graubereichs der laborbasierten Scores. Diese zeichnen sich vor allem durch einen hohen negativen prädiktiven Wert aus und sind daher zum Ausschluss einer höhergradigen Fibrose in Risikokollektiven gut geeignet. Ein Screening auf fortgeschrittene Fibrose in Niedrig-Risiko-Populationen wird dagegen nicht empfohlen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30(6):1356–1362

    Article  CAS  Google Scholar 

  • Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J (2013) Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145(4):782–9.e4

    Article  Google Scholar 

  • Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, Huang Y, Adams LA (2018) Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver Int 38(10):1793–1802

    Article  CAS  Google Scholar 

  • Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-Hubert I, Rousselet MC, Calès P, de Lédinghen V (2016) Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 65(3):570–578

    Article  Google Scholar 

  • Boursier J, Anty R, Vonghia L, Moal V, Vanwolleghem T, Canivet CM, Michalak S, Bonnafous S, Michielsen P, Oberti F, Iannelli A, Van Gaal L, Patouraux S, Blanchet O, Verrijken A, Gual P, Rousselet MC, Driessen A, Hunault G, Bertrais S, Tran A, Calès P, Francque S (2018) Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther 47(10):1387–1396

    Article  CAS  Google Scholar 

  • Canbay A, Kälsch J, Neumann U, Rau R, Hohenester S, Baba HA, Rust C, Geier A, Heider D, Sowa JP (2019) Non-invasive assessment of NAFLD as systemic disease – a machine learning perspective. PLOSOne, Mar 26;14(3):e0214436.

    Google Scholar 

  • Cook N, Geier A, Schmid A, Hirschfield G, Kautz A, Schattenberg JM, Balp MM (2019) The patient perspectives on future therapeutic options in NASH and patient needs. Front. Med 6:61

    Article  Google Scholar 

  • European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388–1402

    Google Scholar 

  • Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48(3):792–798

    Article  CAS  Google Scholar 

  • Harris R, Harman DJ, Card TR, Aithal GP, Guha IN (2017) Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol 2(4):288–297

    Article  Google Scholar 

  • Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA (2008) Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57(10):1441–1447

    Article  CAS  Google Scholar 

  • Mahady SE, Macaskill P, Craig JC, Wong GLH, Chu WCW, Chan HLY, George J, Wong VWS (2017) Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis. Clin Gastroenterol Hepatol 15(9):1453-1460.e1

    Article  Google Scholar 

  • McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM (2017) Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 112(5):740–751

    Article  Google Scholar 

  • Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T (2000) Liver fibrosis in overweight patients. Gastroenterology 118(6):1117–1123

    Article  CAS  Google Scholar 

  • Roeb E, Steffen HM, Bantel H, Baumann U, Canbay A, Demir M, Drebber U, Geier A, Hampe J, Hellerbrand C, Pathil-Warth A, Schattenberg JM, Schramm C, Seitz HK, Stefan N, Tacke F, Tannapfel A, Lynen Jansen P, Bojunga J (2015) S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 53(7):668–723

    Article  CAS  Google Scholar 

  • Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A (2018) Accuracy of the enhanced liver fibrosis test vs fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology 154(5):1369–1379

    Article  Google Scholar 

  • Unalp-Arida A, Ruhl CE (2017) Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology 66(1):84–95

    Article  CAS  Google Scholar 

  • Weiß J, Rau M, Geier A (2014) Non-alcoholic fatty liver disease – epidemiology, clinical course, investigation and treatment. Dtsch Arztebl Int 111:447–452

    PubMed  PubMed Central  Google Scholar 

  • Williams KH, Burns K, Twigg SM (2018) Differing clinical phenotype for higher alanine-aminotransferase (ALT) compared with high-risk NAFLD fibrosis score in type 2 diabetes mellitus. J Diabetes Complications 32(3):321–324

    Article  Google Scholar 

  • Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G (2017) Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 66(5):1486–1501

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andreas Geier .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Geier, A. (2022). Diagnostik: Fibrosescores. In: Geier, A., Canbay, A., Lammert, F. (eds) Nicht-alkoholische Fettlebererkrankung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62484-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62484-5_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62483-8

  • Online ISBN: 978-3-662-62484-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics